1. Abramova, E.B., Astakhova, T.M., Erokhov, P.A., et al., Multiple forms of proteasomes and approaches to their separation, Biol. Bull. (Moscow), 2004, vol. 31, no. 2, pp. 115–120.
2. Almond, J.B. and Cohen, G.M., The proteasome; a novel target for cancer chemotherapy, Leukemia, 2002, vol. 16, pp. 433–443.
3. Atencio, I., Ramachandra, M., Shabram, P., et al., Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines, Cell Growth Differ., 2000, vol. 11, no. 5, pp. 247–253.
4. Ben-Shahar, S., Kolmosh, A., Nadav, E., et al., 26S proteasome-mediated production of an authentic major histo-compatibility class I-restricted epitope from an intact protein substrate, J. Biol. Chem., 1999, vol. 274, pp. 21963–21972.
5. Bochkareva, N.V., Kolomiets, L.A., and Chernyshova, A.L., Is metabolic rehabilitation is required for patients with hyperplasia and endometrial cancer under metabolic syndrome?, Sib. Onkol. Zh., 2010, no. 5, pp. 71–77.